These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12638935)

  • 1. Iron management in renal failure patients--how do we achieve the best results?
    Kosch M; Schaefer RM
    EDTNA ERCA J; 2002; 28(4):182-4. PubMed ID: 12638935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron management in ESRD and the role of the nephrology nurse.
    Robbins KC; Senger JM; Kerhulas S; Fishbane S
    ANNA J; 1997 Apr; 24(2):265-72; quiz 273-4. PubMed ID: 9180431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
    Peacock E; Lindenfeld SM
    ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
    Ahluwalia N; Skikne BS; Savin V; Chonko A
    Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
    Besarab A; Dalton CL
    Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Categorizing the response to Epoetin alfa therapy. Case study of the anemic patient.
    Watson C
    ANNA J; 1999 Dec; 26(6):629-32. PubMed ID: 10876477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.
    Kalantar-Zadeh K; Höffken B; Wünsch H; Fink H; Kleiner M; Luft FC
    Am J Kidney Dis; 1995 Aug; 26(2):292-9. PubMed ID: 7645533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 14. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
    Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of anemia in chronic kidney disease (predialysis) patients: nephrology nursing implications.
    Wish JB; Weigel KA
    Nephrol Nurs J; 2001 Jun; 28(3):341-5. PubMed ID: 12143456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
    Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
    Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy.
    Van Wyck DB
    Nephrol Dial Transplant; 2000; 15 Suppl 3():36-9. PubMed ID: 11032356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations of ferritin as a marker of anemia in end stage renal disease.
    Dennison HA
    ANNA J; 1999 Aug; 26(4):409-14; quiz 419-20. PubMed ID: 10838972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.